"Receptors, Somatostatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter.
Descriptor ID |
D017481
|
MeSH Number(s) |
D12.776.543.750.695.850 D12.776.543.750.720.600.760 D12.776.543.750.750.555.760 D12.776.543.750.750.580.720 D12.776.543.750.750.700.800
|
Concept/Terms |
Receptors, Somatostatin- Receptors, Somatostatin
- Somatostatin Receptors
- SRIH Receptors
- Receptors, Somatotropin Release Inhibiting Hormone
- Receptors, SRIH
- Somatostatin Receptor
- Receptor, Somatostatin
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Somatostatin".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Somatostatin [D12.776.543.750.695.850]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Neuropeptide [D12.776.543.750.720.600]
- Receptors, Somatostatin [D12.776.543.750.720.600.760]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Neuropeptide [D12.776.543.750.750.555]
- Receptors, Somatostatin [D12.776.543.750.750.555.760]
- Receptors, Pancreatic Hormone [D12.776.543.750.750.580]
- Receptors, Somatostatin [D12.776.543.750.750.580.720]
- Receptors, Pituitary Hormone-Regulating Hormone [D12.776.543.750.750.700]
- Receptors, Somatostatin [D12.776.543.750.750.700.800]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Somatostatin".
This graph shows the total number of publications written about "Receptors, Somatostatin" by people in this website by year, and whether "Receptors, Somatostatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 1 | 0 | 1 |
1998 | 2 | 2 | 4 |
2002 | 2 | 0 | 2 |
2003 | 4 | 1 | 5 |
2004 | 2 | 0 | 2 |
2005 | 6 | 0 | 6 |
2006 | 1 | 0 | 1 |
2007 | 0 | 1 | 1 |
2008 | 1 | 1 | 2 |
2009 | 1 | 0 | 1 |
2011 | 3 | 0 | 3 |
2012 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
2017 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2020 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Somatostatin" by people in Profiles.
-
Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma. Clin Cancer Res. 2024 02 16; 30(4):680-686.
-
Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide. J Med Chem. 2024 02 22; 67(4):2425-2437.
-
Gastroenteropancreatic neuroendocrine neoplasm imaging: standard reporting templates. Abdom Radiol (NY). 2022 12; 47(12):3986-3992.
-
High-Contrast Detection of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Mol Pharm. 2022 11 07; 19(11):4241-4253.
-
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. Eur J Cancer. 2022 02; 162:221-236.
-
A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021 Feb; 24(1):1-13.
-
Pediatric applications of Dotatate: early diagnostic and therapeutic experience. Pediatr Radiol. 2020 06; 50(7):882-897.
-
Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery. Clin Cancer Res. 2019 07 15; 25(14):4332-4342.
-
Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Clin Nucl Med. 2017 Jun; 42(6):436-443.
-
Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR. Drugs. 2016 Sep; 76(13):1235-1243.